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A considerable body of experimental evidence (1) supports the Jerne hypothesis  (2) 
that  idiotypes are important  in the autoregulation  of B  cells.  Although  the original 
concept  was  limited  to  regulatory  antibodies  that  recognized  individually  specific 
determinents  (idiotypes)  located  in  the  variable  regions  of other  immunoglobulin 
molecules,  subsequent  studies  (3-6)  showed  that  certain  T  cells  also  recognized 
idiotypes.  Anti-idiotypic  T  cells  have been  shown  to include  helper  and  suppressor 
cells that regulate  individual  B cell clones. 
It has been difficult  to develop a  precise understanding  of the events that occur in 
a  B  cell  when  it  is  regulated  by  anti-idiotypic  T  cells  or  antibodies  because  in 
conventional immune cell samples, the specifically regulated B cells comprise a minute 
fraction  of the  sample  that  is  being  studied.  To  circumvent  this  limition,  we  have 
studied  the 2,4,6-trinitrophenyl 1 (TNP)-specific BALB/c plasmacytoma MOPC-315; 
it is a  monoclonal  B cell population  that  is responsive to idiotype-specific and TNP- 
antigen-specific  immunoregulatory  signals  (7). 
Previous  studies  identified  three  idiotype  (Id31~)-specific events  that  followed  im- 
munization  of BALB/c  mice with  the  IgA anti-TNP  antibody  (M315)  produced  by 
MOPC-315:  (a) induction  of anti-idiotypic  (a-Id  8~5) antibodies  predominantly  of the 
IgG1  subclass  (8),  (b)  development  of  a-Id  815  suppressor  T  cells  (9,  10),  and  (c) 
establishment  of  Id3aS-specific  protection  from  challenge  with  lethal  numbers  of 
MOPC-315  cells  (11).  Subsequent  studies  of MOPC-315  cells enclosed  in peritoneal 
diffusion  chambers  (9)  suggested  that:  (a)  anti-Id ~15  antibodies  inhibited  surface 
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membrane expression of M315, and (b) anti-Id  315 suppressor T  cells inhibited secretion 
of M315.  Recently, we showed that anti-Id  als antibodies inhibited surface membrane 
expression of M315 in vitro without influencing M315 secretion or MOPC-315 growth 
or viability.  2 
In this paper, an in vitro system was used to more precisely analyze the mechanism 
of inhibition of M315 secretion mediated by a-Id  31s suppressor T  cells. These studies 
have established that  a-Id  315 suppressor T  cells (a)  are Lyt-l-2  + cells that express a 
surface membrane binding site specific for Id  a15, (b) mediate suppression via an Id  alS- 
specific diffusable product,  (c)  act  directly on  M315-seereting cells, and  (d)  inhibit 
M315 secretion by a  selective and reversible inhibition of M315 biosynthesis. 
Materials  and  Methods 
Chemicals and Reagents.  2,4,6-trinitrobenzene sulfonate,  protease type VI,  and  Sepharose 
6MB  were  obtained  from  Sigma  Chemical  Co.,  St.  Louis,  MO.  Sheep  erythrocytes were 
purchased from Colorado Serum Co., Denver, CO. Rabbit anti-mouse IgA serum was obtained 
from Gateway Immunosera, St. Louis, MO, and guinea pig complement was obtained from 
Grand Island Biological Co., Grand Island, NY. Fetal bovine serum (lot 30351)  was purchased 
from KC Biologicals, Lenexa, KS. 
Mice.  BALB/c mice were purchased from West Seneca Laboratories, West Seneca, NY. 
The mice were offered, ad lib., a  standard pellet chow and tap water containing 60 mg/liter 
aureomycin (American Cyanimid Corp., Pearl River, NY). 
Plasmacytomas and Myeloma Proteins.  An in vitro adapted line of MOPC-315 was established 
from an aseites tumor and had been maintained in continuous culture for ~3 yr at the time of 
these studies. The cells were grown in RPMI  1640 medium supplemented with 10% fetal calf 
serum, 2 mM L-glutamine, 1 mM sodium pyruvate, essential and nonessential amino acids, 25 
mM Hepes, 100 IU/ml penicillin, 100 Izg/ml streptomycin, and 5 X 10  -5 M 2-mercaptoethanol. 
Greater than 99% of these cells express cytoplasmic IgA detected by immunofluorescence, 80- 
90% express surfce M315  that  is visualized with a  TNP-sheep erythroeyte rosette assay (12), 
and 40-50% secrete sufficient M315  to form an anti-TNP plaque-forming cells (PFC) in an 
indirect Jerne assay (13).  The cells were fed three times a  week and split to ~5 X  10~viable 
cells/ml after reaching a density of ~ 1.5 ×  10%ells/ml. 
M315 and M460 were purified as described previously (11). 
Induction and Isolation of ldiotype-specific T Cells.  BALB/c mice were hyperimmunized with a 
mildly reduced and alkylated form of M315 (RA315) in six injections at 1-wk intervals of 200 
#g in 0.2 ml, as previously described (9).  3 d  before killing, the hyperimmunized mice were 
boosted intravenously with 50 #g of RA315 in phosphate-buffered saline (PBS). Spleen cells 
were collected aseptically and erythrocytes lysed with NH4-C1-Tris, pH 7.4,  and then passed 
through a nylon wool column (typically, 1.6 X  l0  s cells/g of dry nylon-wool). The nylon wool- 
nonadherent  cells were collected, subjected to various specific cell separation protocols (see 
below), and added to MOPC-315 cells at various T  cell:MOPC-315 cell ratios. 
The co-cultures were harvested after 24  h  of incubation at  37°C.  MOPC-315  cells were 
counted and their viability determined by trypan blue dye exclusion. MOPC-315 cells express- 
ing  surface  membrane  M315  were  quantitated  as  TNP-rosette-forming cells,  and  M315- 
secreting cells were quantitated as TNP-PFC. 
Co-Cultures and Marbrook-like Cultures.  1 ×  105  MOPC-315  cells were mixed with  various 
numbers of either RA315-immune T cells or normal T cells and were incubated at 37°C in 1.0- 
ml cultures in 24-well culture plates (Costar 3524; Costar, Data Packaging, Cambridge, MA). 
In some experiments 0.2-ml co-cultures were incubated in 96-well flat-bottomed plates (Costar 
3596).  In experiments with Marbrook-like cultures, 1 ×  105 MOPC-315 cells were placed in the 
upper chamber (PC-2; Adaps, Inc., Dedham, MA) and separated from the lower chamber by 
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a  0.22-#m membrane  (Millipore Corp., Bedford, MA). The lower chamber containing the T 
ceils was formed by the well of a 24-well plate as described by Ullrich and Zolla-Pazner (14). 
Cell Separation by  Affinity  Chromatography.  Immunoadsorbent  columns  were  prepared  by 
coupling RA315, RA460, monoclonal anti-Lyt-1.2 (clone 53-7.313),  or monoclonal anti-Lyt-2.2 
(clone 53-6.72)  to Sepharose 6MB using the procedure described elsewhere (15).  (Clones 53- 
7.313  and  53-6.72  were obtained  from  Noel Warner,  University of New  Mexico School of 
Medicine, Albuquerque, NM.) Briefly, 2-5 mg of each antibody was added to each milliliter of 
cyanogen bromide-activated Sepharose, achieving a coupling efficiency of>90%. 1-ml antibody- 
coupled gel columns were constructed using a T-B syringe (B-D, Rutherford, N  J) containing a 
nylon-wool plug. After washing with RPMI  1640 medium supplemented with  10% fetal calf 
serum  and  10  mM  Hepes,  1-2  ×  107  nylon wool-nonadherent T  cells were added to each 
column, incubated for 30 min at room temperature, and then nonadherent cells were gently 
eluted. In one set of experiments, the cells bound to RA315-Sepharose 6MB were eluted with 
soluble RA315 in PBS at a concentration of 2.0 mg/ml. In all other experiments the nonadherent 
cells were used. 
[aH]Leucine  Incorporation Studies.  Incorporation  of [3H]leucine  (76  Ci/mmol;  Amersham 
Corp., Arlington Heights, IL) into M315  or total cell protein was assayed by culturing the 
MOPC-315 cells with 50 #Ci of the isotope in each milliliter of leucine-free minimum essential 
medium (Grand Island Biological Co.) supplemented with 10% fetal calf serum. 
Co-cultures of myeloma cells and T  cells were incubated for 24 h, after which they were 
washed  and  pulsed with  isotope.  At  harvest,  the  amount  of [aH]leucine incorporated  into 
secreted M315  was  quantitated by specific immunoprecipitation of the supernatant  by the 
procedure described elsewhere (16). The intracellular M315 was similarly immunoprecipitated 
after a  30-min treatment of the washed cells with 0.5%  nonidet P-40 (NP40)  (Jet Propulsion 
Laboratory, Pasadena, CA) and removal of subcellular organelles by microcentrifugation. To 
correct for the radioactivity nonspecifically bound in the immunoprecipitates, control precipi- 
tates of normal rabbit ),-globulins and  goat anti-rabbit globulin serum were formed in  the 
labeled cell extracts or supernatants and processed along with experimental groups. This level 
of nonspecifically bound  radioactivity  (which  was  ~1%  of  the  total  counts  added)  was 
subtracted from each experimental group. 
The same procedures were used for [aH]leucine incorporation studies in the Marbrook culture 
system, with the exception that 48 h elapsed before the 24-h pulse with the isotope. In addition, 
cold 5% trichloroacetic acid (TCA) precipitation was used to quantitate the amount of [aH]- 
leucine incorporated into total intracellular protein in MOPC-315 cells. 
Data Analysis.  Each experiment was  performed a  minimum of three times and  the data 
reported as the mean ±  1 SEM. 
Results 
Inhibition  of M315  Secretion  by  IdalS-specific  T  Cells  In  Vitro.  Previous  studies  (9) 
showed that spleen cells from Ida15-immune mice could adoptively transfer inhibition 
of M315 secretion to normal mice and that the transfer was abrogated by treating the 
spleen  cells with  anti-0  (rabbit  anti-mouse brain  antisera)  and  complement  before 
transfer.  Therefore,  nylon  wool-purified splenic T  lymphocytes from  Id315-immune 
mice were co-cultured at various concentrations with MOPC-315  cells in vitro. The 
data,  shown  in  Table  I,  show  that  after  a  24-h  co-culture with  the  IdalS-immune 
spleen  cells,  there  was  no  effect  on  MOPC-315  viability  or  surface  membrane 
expression  of M315  when  compared  with  control  cultures  that  contained  normal 
splenic T  cells mixed with MOPC-315 cells. In contrast, IdaXS-immune T  cells inhibited 
the frequency of M315-secreting cells by >90% compared with controls when the ratio 
of immune  effector T  cells to MOPC-315  cells was  200:1.  As shown  in Table II, a 
direct relationship exists between  the dose of immune effector T  cells added to the 
MOPC-315  cells and  the level of inhibition of secretion. Almost total inhibition of 
secretion was  observed at  an  800-fold excess of Id315-immune T  cells, whereas only GARY  L.  MILBURN  AND  RICHARD  G.  LYNCH  855 
TABLE  I 
Effect of ld315-specific T Cells on MOPC-315 Cells In Vitro 
Percentage  Percentage 
Effector:MOPC-315  of MOPC-  of MOPC- 
cell ratio*  Effector cells  Viability  315 with  315 cells 
surface  that secrete 
M315  M315 
MOPC-315 cells alone  None  93 4- 2:~  89 4- 2 
50:1  Normal spleen T cells  86 4- 3  89 4- 2 
100:1  Normal spleen T cells  85 4- 5  84 4- 3 
200:1  Normal spleen T cells  83 4- 5  82 4- 3 
44+ 3 
414-5 
404-4 
384-3 
50:1 
100:1 
200:1 
RA315-immune spleen T cells  78 4- 3  82 4- 4 
RA315-immune spleen T cells  78 4- 5  79 4- 5 
RA315-immune spleen T cells  76 4- 2  77 4- 5 
364-4 
84-2 
34-2 
* MOPC-315  cell  number was typically  10  s viable cells/ml, and the effector cell 
according to the ratio indicated. 
:~ Mean 4- I SEM for three experiments. 
number was adjusted 
TABLE  II 
Dose-dependent Suppression of M315 Secretion 
Effector:MOPC-315 cell 
ratio*  Effector cells 
MOPC-315 cells alone  None 
Percentage 
of MOPC- 
315 cells 
that secrete 
M315 
43 4- 3:~ 
100:1 
400:1 
800:1 
Normal spleen T cells 
Normal spleen T cells 
Normal spleen T cells 
414-3 
394-2 
364- 3 
25:1 
50:1 
100:1 
200:1 
400:1 
800:1 
RA315-immune spleen T cells 
RA315-immune spleen T cells 
RA315-immune spleen T cells 
RA315-immune spleen T cells 
RA315-immune spleen T cells 
RA315-immune spleen T cells 
41 
32 
12 
8 
3 
2 
* MOPC-315 cell number was held constant at 10  ~ viable cells/ml. 
:~ Mean 4- 1 SEM for three experiments. 
+4 
4-3 
:1:5 
:t:3 
4- 1 
4-1 
minimal  effects  were  observed  when  equivalent  numbers  of normal  splenic  T  cells 
were added  to MOPC-315  cultures. 
Characterization of the IdalS-specific  Effector  Cell.  Although  inhibition of M315  secre- 
tion by nylon wool-passed cells implied that the effector cell was a  T  cell, more direct 
evidence was sought. Treatment  of IdalS-immune spleen cells with anti-0 +  guinea pig 
complement  (C')  eliminated  the secretory suppression,  whereas normal  rabbit  serum 
+  C' had  no effect  (data not shown). 
To  determine  the Lyt  phenotype  of the effector T  cell,  RA315-immune  splenic T 
cells were  applied  to either anti-Lyt-1  or anti-Lyt-2  columns.  The  nonadherent  cells 
from each column  were then co-cultured with MOPC-315  cells. The  results, shown  in 
Table  III,  show  that  cells  that  passed  through  the  anti-Lyt-1  column  still  retained 856  SUPPRESSION OF MOPC-315  SEGRETION IN VITRO 
TABLE  III 
Id sln-spedfic  T Suppressor Cells Are Lyt-1-2 + 
Effeetor:MOPC-315 cell  Treatment of added  Percentage of  MOPC-315 cells  ratio  RA315-Immune T cells  that secrete M315 
MOPC-315 cells alone  None  55 4- 1" 
50:1  No treatment  43 4- 1 
100:1  No treatment  8 4- 1 
50:1  Lyt-2.2 depletion:]:  54 4- 2 
100:1  Lyt-2.2 depletion  49 4- 3 
50:1  Lyt-l.2 depletion§  14 4- 2 
100:1  Lyt-1.2 depletion  6 4- 1 
50:1  Lyt-2.2  depletion  and  19 4- 3 
50:1  Lyt-l.2 depletionll 
* Mean 4- 1 SEM for three experiments. 
:~ Effector cells were depleted by passage over an anti-Lyt-2.2-Sepharose 6MB 
column. 
§ Effector cells were depleted by passage over an anti-Lyt-l.2-Sepharose  6MB 
column. 
[] Equal numbers of nonadherent cells from each column were mixed and used 
as effeetors. 
their  suppressive  activity,  whereas  the  anti-Lyt-2  column  depleted  the  suppressor 
activity. Taken together, these data establish the phenotype of the effector T  cells as 
Lyt-l-2  +.  Furthermore,  when  equal  numbers  of Lyt-l-depleted and  Lyt-2-depleted 
cells were mixed and added to MOPC-315 cultures, the level of suppression observed 
was  the  same  as  with  the  same  number  of Lyt-l-depleted cells alone.  This  result 
suggests that  (a) Lyt-1 + cells did not have any augmenting or inhibiting effect on the 
Lyt-2  + effectors, and (b) the Lyt-1+23  + cells, which were depleted by passage through 
either  column  in  these  mixing  experiments,  were  not  the  effectors  and  were  not 
required  at  the  effector  stage  of M315  secretory  inhibition.  Furthermore,  we  also 
established that macrophages were not required at the effector stage (data not shown). 
To investigate the idiotype specificity of secretory inhibition, columns of Sepharose 
6MB conjugated with RA315 or RA460 were prepared. RA460 is the mildly reduced 
and  alkylated  IgA  anti-TNP  myeloma  protein,  M460,  produced  by  MOPC-460. 
M315  and  M460  have  dissimilar  idiotypes.  RA315-immune  splenic  T  cells  were 
applied to the columns, and the nonadherent cells from each column were tested for 
suppressive activity on  MOPC-315  cells. The data  (Table IV)  show that  the T  cells 
that  mediated inhibition of M315  secretion bound to the RA315-Sepharose but  not 
to  the  RA460-Sepharose  column.  Furthermore,  T  cells  eluted  from  the  RA315- 
Sepharose column with soluble RA315 at a  concentration of 2  mg/ml were enriched 
in suppressor activity.  Significant suppression was  observed at  a  T  celI:MOPC-315 
cell ratio of only  12:1, and inhibition was virtually total at higher ratios. Few, if any 
cells were retained by the RA460-Sepharose column, and elution with soluble RA315 
failed to release cells. When soluble M315  (100 #g/ml)  was added to the euhures,  it 
prevented  the  T  cells  from  suppressing  M315  secretion  (data  not  shown).  These 
observations demonstrate that IdalS-specific  suppressor T  cells have surface recognition GARY L.  MILBURN AND RICHARD G.  LYNCH  857 
TABLE  IV 
Depletion and Enrichment of IdaZS-specific T Cells 
Percentage of 
Effector:MOPC-315  Treatment of added RA315  MOPC-315 
cell ratio  immune T cells  cells that 
secrete M315 
MOPC-315 cells alone  No treatment  43 +  3* 
50:1  No treatment  12 ±  3 
100:1  No treatment  8 ±  3 
200:1  No treatment  3 :tz 1 
50:1  Id  46° absorption:~  16 :l: 4 
100:1  Id  46° absorption  10:1:5 
200:1  Id  46° absorption  7 -t- 2 
50:1  Id  al~ absorption§  35 -t- 3 
100:1  Id  az~ absorption  36 +  5 
200:1  Id  a15 absorption  34 :t: 6 
12:1 
25:1 
50:1 
Eluted from Id  al5 absorbant[J  11 ±  5 
Eluted from Id  a15 absorbant  4 +  4 
Eluted from Id  s15 absorbant  1 +  1 
* Mean +  1 SEM for three experiments. 
:~ RA315-immune spleen  T  cells were passed  over an  Id4°°-Sepharose  6MB 
column, and the nonadherent cells were used as effectors. 
§ RA315-immune spleen  T  cells were passed  over an  Id31S-Sepharose 6MB 
column, and the nonadherent cells were used as effectors. 
[[ Cells  that  adhered  to the IdalS-Sepharose  6MB  column were eluted with 
soluble RA315 in PBS at a concentration of 2 mg/ml. 
structures  that can  (a) bind to M315  idiotypes and  (b)  distinguish  between M315 and 
M460  idiotypes. 
Kinetics of Inhibition of M315 Secretion.  All the previous experiments measured M315 
secretion  after MOPC-315  cells had  been  co-cultured with the suppressor  T  cells for 
24 h. To determine the kinetics of inhibition, we determined the frequency of secretory 
cells at  2-h intervals after the addition  of RA315-immune  splenic T  cells to MOPC- 
315  cell cultures.  Fig.  1  shows  that  inhibition  of M315  secretion  was  first  detected 
after  6  h  of co-culture  and  progressed  until  an  inhibition  of 80-90%  of the  control 
PFC  frequency was observed  at  24 h. This result  suggests that  the regulatory T  cells 
were already  programmed  for the suppressive  activity when  they were added  to the 
culture and probably  did not require further proliferation or differentiation.  Further- 
more, because  MOPC-315  cells were secreting M315  at  the time that  the suppressor 
cells were  added  to  the  culture,  the  suppressor  T  cells  acted  directly  on  the  actual 
antibody-secreting cell rather  than  on a  precursor to the antibody-secreting cell. 
Inhibition of M315 Synthesis by IdatS-specific Suppressor T  Cells.  Inhibition  of M315 
secretion  could have resulted  from  (a)  inhibition  of M315  release without  inhibition 
of M315  synthesis,  (b)  inhibition  of transcription  or translation  of M315  messenger 
RNA  (mRNA),  or  (c)  an  increased  rate  of intracellular  degradation  of M315.  The 
first  possibility  was  considered  unlikely  because  continued  M315  synthesis  in  the 
presence  of  a  block  in  release  would  be  expected  to  result  in  the  intracellular 858  SUPPRESSION  OF  MOPC-315  SECRETION  IN  VITRO 
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FIG.  1.  Data  from a  representative experiment showing the time-course of inhibition  of M315 
secretion from MOPC-315 cells in vitro. (O)  nylon wool-purified T  cells from Ida]5-immune donors; 
(0) nylon wool-purified T  cells from normal donors. See Material and Methods for details. 
TABLE V 
T Cell Suppression of M315 Synthesis and Secretion 
Effector cells added to MOPC-315 ceils 
[SH]Leucine incorporated into M315" 
Supernatants:~  Intracellular~ 
None  34,119 ±  2,53911  144,868 +  2,319 
100 ×  normal spleen T  cells  31,919 ±  3,630  108,329 ±  1,705 
100 ×  RA315-immune spleen T  cells  1,285  ±  245  2,932 ±  1,212 
* Effector and tumor cells were co-cultured for 24 h  before a  24-h pulse of [SH]leucine, specific immuno- 
precipitation of M315 was then used. 
~: 1 ml supernatant from the 48-h co-culture was immunoprecipitated for [aH]leucine incorporation into 
secreted M315. 
§ The co-cultured cells were lysed with 0.5% NP40, the subcellular organelles removed by centrifugation, 
and the supernatant immunoprecipitated. 
II Mean cpm ±  1 SEM for three experiments. 
accumulation of large masses of cytoplasmic M315.  In a previous study, tunicamycin 
was shown to inhibit secretion but not synthesis of M315  (16),  and this was accom- 
panied  by a  striking  dilatation  of endoplasmic  cisternae  filled  with  M315.  In  the 
present studies, inhibition of M315 secretion by suppressor T  cells was not accompa- 
nied by ultrastructural changes in the MOPC-315 cells (data not shown). 
To evaluate changes in M315 synthesis, we measured incorporation of [aH]leucine 
into secreted and intracellular M315. We observed a >90% inhibition of incorporation 
into both intracellular and secreted M315  in the presence of Id81Lspecific suppressor 
T  cells (Table V). 
To  determine  whether  inhibition  of M315  synthesis  was  selective,  studies  were 
performed in a Marbrook apparatus so that the total protein synthesis by MOPC-315 GARY  L.  MILBURN  AND  RICHARD  G.  LYNCH 
TABLE  VI 
Diffusable Product Selectively Inhibits M315 Synthesis* 
859 
MOPC-315 cells added to upper Marbrook 
chamber with lower chamber containing 
[SH]Leucine incorporation into 
MOPC-315 
TCA-precipitated 
M315:~  protein§ 
Media 
200 ×  normal spleen T  cells 
200 ×  RA315 immune spleen T  ceils 
124,936  -4- 5,15811  236,639 -,'- 6,041 
107,254:1:: 2,593  210,733  +  6,338 
9,092:1:  1,510  112,213:1:4,481 
* Effector and tumor cells were co-cultured in Marbrook culture system for 48 h before 24-h 
pulse of [aH]leucine. 
:~ Specific immunopreeipitation of M315 was used. 
§ 5% cold TGA precipitation. 
II Mean cpm +  1 SEM for three experiments. 
cells could be measured.  It was possible to use the Marbrook apparatus because in 
pilot studies (data not shown) we demonstrated that the IdalS-specific T cells mediated 
the suppression of M315 secretion across the 0.22-#m pore membrane of the Marbrook 
chamber. [aH]leucine incorporation into intracellular M315 and the TCA-precipitable 
fraction  of MOPC-315  ceils  showed  that  the  inhibition  of protein  synthesis  was 
selective for M315  (Table VI). When suppressor T  cells and MOPC-315 cells were 
incubated in separate compartments of the Marbrook chambers for 48 h  and were 
then pulsed with [aH]leucine for 24 h, we observed an ~50% decrease in total protein 
synthesis in MOPC-315 cells, and the entire decrement could be accounted for by the 
decrease in M315 synthesis (Table VI). These findings strongly suggest that inhibition 
of M315 secretion by the suppressor T  cell product is achieved by a selective down- 
regulation  of M315  synthesis.  Although  the  inhibition  of secretion  by  increased 
intracellular degradation of M315  has not been formally ruled out, this possibility 
appears highly unlikely for two reasons:  (a) because non-M315 protein synthesis was 
not influenced by the suppressor T  cells, intracellular catabolism of M315 would have 
to be highly selective; (b) when secretion but not synthesis of M315 was blocked by 
tunicamycin (16) no evidence for intracellular degradation of M315 was detected. We 
established  that  inhibition  of M315  biosynthesis  was  reversible  (data  not  shown). 
When suppressed MOPG-315 cells were removed from the Marbrook chambers and 
cultured  in  the  absence of T  cells for several days, the initial  frequency of M315- 
secreting ceils was reestablished. Furthermore, the inhibition could also be quickly 
reversed by a brief treatment of the suppressed MOPC-315 cells with pronase, before 
plaquing, corroborating earlier in vivo results (9,  10). 
Discussion 
The studies presented here represent extensions of previous in vivo findings and 
have begun to establish the mechanism of inhibition of M315 secretion from MOPG- 
315  cells  that  is  mediated  by IdeaS-specific  suppressor T  cells.  Tahese studies  have 
established  that  inhibition  of M315  secretion  is  mediated  by  a  Lyt-2  ÷  cell  that 
expresses a surface membrane receptor for Id  315. The suppressor signal is a diffusable 
product  that  acts  directly on  M315-secreting  myeloma  cells.  Inhibition  of M315 
secretion is T cell dose-dependent, IdalS-specific, reversible, and results from inhibition 860  SUPPRESSION  OF  MOPC-315  SECRETION  IN  VITRO 
of M315 synthesis. The inhibition of protein synthesis in the myeloma cell is selective 
for the myeloma protein. 
The precise molecular mechanism of selective inhibition of M315 synthesis is yet to 
be established. It is highly unlikely that engagement per se of surface membrane Id  315 
by an anti-Id  31s product of the T  cell could account for suppression of synthesis. The 
engagement  of surface  membrane  Id  315  on  MOPC-315  cells  by  a-Id  315  antibodies 
results in a clearance of surface Id  31~ without any effect on M315 secretion.  2 Further- 
more, engagement of surface Id  315 by TNP-carrier in the presence of carrier-specific 
helper T  cells results in an increase of M315 secretion (17). These findings (and others 
reviewed in reference 7) support the view that surface membrane Id  315 functions as a 
focusing device for a multiplicity of immunoregulatory effectors and that the quality 
and  intensity of the regulatory effect observed is probably dictated by the effector 
that is focused and not simply by engagement of the membrane Id  3a5 per se. 
It is likely that the selective inhibition of M315 synthesis is achieved at the level of 
transcription or translation. Translational control could involve mRNA processing or 
degradation,  but  would  have  to  be  highly  selective  to  account  for  our  findings. 
Control at the level of transcription is more likely and is consistent with the kinetics 
of inhibition reported here. The time-course of inhibition  (Fig.  1)  is similar to that 
reported for the half-life of mRNA for both heavy and light immunoglobulin chains 
(18). Studies in progress using Northern blot analysis of suppressed MOPC-315 cells 
might help clarify the precise mechanism of this control. An interesting aspect in this 
regard  is  the  persistent  expression  of surface  membrane  M315  in  cells  in  which 
secretory M315 is suppressed. Although the maintenance of membrane M315 might 
be accounted for by a  long turnover time or a  large intracellular pool of membrane 
M315,  it  could  also  reflect  separate  regulation  of the  biosynthetic  pathways  for 
membrane and secretory M315. 
The experiments using Marbrook chambers establish that a diffusable effector acts 
on  the  target  myeloma cell.  Although  the  present  studies  have  not  distinguished 
between a product produced by the a-Id  3~5 T  cell or by another T  cell in the immune 
cell sample,  preliminary results using an  a-Id~a~-specific  T  cell hybridoma indicate 
that  the effector is a  product of the a-Id  31~ T  cell (G. L. Milburn and R. G. Lynch, 
unpublished  observations). The present  studies  clearly establish  that  suppressor T 
cells can act directly on B cells as late in B cell development as the actual antibody- 
secreting cell. These suppressor T  cells do not work indirectly by suppressing a helper 
T  cell and they do not require an adherent acessory cell. Several laboratories have 
presented data suggesting that suppressor T  cells can act directly on nonneoplastic 
antibody-secreting cells (19-22). 
Finally, hapten-specific myelomas and other neoplastic lymphoid clones (23, 24) 
provide unique opportunities to establish the molecular and cellular mechanisms of 
B cell regulation. An elegant example of their utility is the recent study of Abbas et 
al.  (25), in which myeloma-myeloma hybrids were used to analyze immunoglobulin 
regulation. Coupled with recombinant DNA technology, the study of cloned B cells 
might lead to an understanding of B cell regulation in precise molecular terms. 
Summary 
In previous studies, BALB/c mice immunized with the trinitrophenyl-specific IgA 
protein  (M315)  produced by MOPC-315  developed idiotype (Id315)-specific  T  cells GARY L. MILBURN AND  RICHARD G.  LYNCH  861 
that suppressed M315 secretion in vivo. In the present  in vitro studies, we show that 
inhibition of M315 secretion is mediated by a 0 +, Lyt-1-2  + cell that expresses a surface 
membrane receptor for Id  a15. The suppressor signal is a  diffusable product that acts 
directly on M315-secreting myeloma cells. Inhibition of M315 secretion is T  cell dose- 
dependent,  IdalS-specific,  reversible,  and  occurs  without  any  effect  on  MOPC-315 
growth,  viability,  or  surface  membrane  expression  of M315.  Inhibition  of M315 
secretion  results  from a  selective  inhibition  of M315  synthesis  in the myeloma cell. 
These studies provide new insight into the mechanisms of direct B cell regulation by 
idiotype-specific T  cells. 
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